<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Analysis of Laboratory Data</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.5.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Biosimilar-Trials.html">Statistical Considerations for the Design and Analysis of Biosimilar Trials</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Alternatives-to-Power.html">Bayesian methods - Alternatives to Power</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
    <li>
      <a href="03-SSC-Case-Continuous-Endpoint.html">Sample Size Determination for Continuous Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Categorical-Endpoint.html">Sample Size Determination for Categorical Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-Determination-for-Counts-and-Rates.html">Sample Size Determination for Counts and Rates</a>
    </li>
    <li>
      <a href="03-SSC-Case-Survival-Endpoint.html">Sample Size Determination for Survival Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Repeated-Measures.html">Sample Size Determination for Repeated Measures</a>
    </li>
    <li>
      <a href="03-SSC-IA-Sequential-Design.html">Statistical Considerations for Group Sequential Design</a>
    </li>
    <li>
      <a href="03-SSC-IA-Adaptive-Design.html">Statistical Considerations for Adaptive Design</a>
    </li>
    <li>
      <a href="03-SSC-Multiple-Test.html">Sample Size for Multiple Test</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands-Framework.html">Estimands Framework</a>
    </li>
    <li>
      <a href="04-Design-Estimands-Practice.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Complex-Sequential-Trials.html">Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Adaptive-Clinical-Trials.html">Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Bayesian-Clinical-Trials.html">Bayesian Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Single-Arm-Clinical-Trials.html">Single Arm Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-Design-and-Evaluation.html">Diagnostic Study-Design and Evaluation</a>
    </li>
    <li>
      <a href="04-Design-Diagnostic-Study-MRMC.html">Diagnostic Study-Multireader Multicase (MRMC)</a>
    </li>
    <li>
      <a href="04-Design-Vaccine-Design.html">Vaccine Trials</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
    <li>
      <a href="04-Design-Regulatory-Submission.html">Regulatory Submission from Stats Perspective</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot-Time-To-Event.html">Time to Event Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-PRO-Data.html">Patient Reported Outcome Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-SSC-and-Power-Calculation.html">Sample Size and Power Calculations Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Correlation.html">Correlation Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Model-Table.html">Clinical Data and Model visualization</a>
    </li>
    <li>
      <a href="05-Plot-ScatterPlot.html">Scatter and Line Plot</a>
    </li>
    <li>
      <a href="05-Plot-BarPlot.html">Bar Chart</a>
    </li>
    <li>
      <a href="05-Plot-PieChart.html">Pie Chart</a>
    </li>
    <li>
      <a href="05-Plot-BoxPlot.html">Box Plot</a>
    </li>
    <li>
      <a href="05-Plot-Histogram.html">Histogram</a>
    </li>
    <li>
      <a href="05-Plot-Forest-Plot.html">Forest Plot</a>
    </li>
    <li>
      <a href="05-Plot-Flow-Chart.html">Flow Chart</a>
    </li>
    <li>
      <a href="05-Plot-Some-Interesting.html">Some Interesting Plots</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-calculator"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Linear-Regression.html">Linear Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SSD.html">Safety Signal Detection and Evaluation</a>
    </li>
    <li>
      <a href="06-Analysis-Meta-Analysis.html">Meta Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Time-Series-Analysis.html">Time Series Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-SEM.html">Structural Equation Modeling</a>
    </li>
    <li>
      <a href="06-Analysis-Factor-Analysis.html">Factor Analysis</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-bar-chart"></span>
     
    Machine Learning
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="07-ML-Bayesian-Theory.html">Bayesian Theory</a>
    </li>
    <li>
      <a href="07-ML-Bayesian-Analysis.html">Bayesian Analysis</a>
    </li>
    <li>
      <a href="07-ML-Regularization-Penalized-Regression.html">Regularization Penalized Regression</a>
    </li>
    <li>
      <a href="07-ML-Loss-Regression.html">Loss Functions in Machine Learning</a>
    </li>
    <li>
      <a href="07-ML-PCA.html">Principal Component Analysis</a>
    </li>
    <li>
      <a href="07-ML-KNN.html">K-Nearest Neighbors</a>
    </li>
    <li>
      <a href="07-ML-SVM.html">Support Vector Machine</a>
    </li>
    <li>
      <a href="07-ML-Tree-Models.html">Tree Models</a>
    </li>
    <li>
      <a href="07-ML-LDA.html">Linear Discriminant Analysis</a>
    </li>
    <li>
      <a href="07-ML-Cluster-Analysis.html">Cluster Analysis</a>
    </li>
    <li>
      <a href="07-ML-Neural-Networks.html">Neural Network</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-stethoscope"></span>
     
    Clinical Analysis (ADaM)
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="08-Clinical-Disposition-Baseline.html">Disposition and Baseline</a>
    </li>
    <li>
      <a href="08-Clinical-Efficacy-Continuous.html">Efficacy Continuous Analysis</a>
    </li>
    <li>
      <a href="08-Clinical-Efficacy-Responder.html">Efficacy Responder Analysis</a>
    </li>
    <li>
      <a href="08-Clinical-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="08-Clinical-Pharmacokinetics-Analysis.html">Pharmacokinetics Analysis</a>
    </li>
    <li>
      <a href="08-Clinical-Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="08-Clinical-Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="08-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
<li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Analysis of Laboratory Data</p></h1>

</div>


<div id="statistical-consideration-of-lbs" class="section level1">
<h1>Statistical Consideration of LBs</h1>
<div id="introduction" class="section level2">
<h2>Introduction</h2>
<p>Laboratory specimens are integral to clinical trials, serving as
primary indicators of systemic toxicities and providing crucial safety
information. Their objective nature and direct relation to organ
function make laboratory data indispensable for early detection of
adverse effects, often before clinical symptoms become apparent. This
routine collection and analysis of laboratory data is fundamental in
clinical trials aimed at evaluating new therapies, where safety
monitoring is a critical component.</p>
<p><strong>Key Points:</strong> 1. <strong>Routine Collection</strong>:
Lab data are routinely collected according to prespecified schedules to
monitor patient safety throughout clinical trials. 2.
<strong>Unscheduled Tests</strong>: Investigators might order
unscheduled tests to follow up on identified toxicities or to
investigate suspicious clinical observations.</p>
</div>
<div id="common-laboratory-tests" class="section level2">
<h2>Common Laboratory Tests</h2>
<p>The most common categories for laboratory tests for human clinical
trials are Hematology, Blood (or Serum) Chemistry, Urinalysis and
Coagulation. Less common categories are Microbiology, Stool specimens,
and testing for specific drugs. While the grouping specific tests
sometimes varies from case report form to case report form, in general
the Hematology category is of those tests involving the cellular
components of the blood, while Blood Chemistry focuses on the plasma
components. The Urinalysis group are those tests involving components of
the Urine. Coagulation Tests are those that involve blood clotting,
these are sometimes grouped into the Hematology test category.
Microbiology tests are those testing for the presence of specific
bacteria, and fungi.</p>
<p>The determination of what tests are actually collected during a
clinical trial in some degree is determined by the drug being studied
and is generally defined in the protocol. Below is a list of commonly
collected laboratory tests grouped by category. The groupings are not
hard and fast and different studies sometimes group the lab tests in
different groups. For example, combining coagulation and hematology into
one group, is a common practice.</p>
<ol style="list-style-type: decimal">
<li><strong>Hematology</strong>
<ul>
<li><strong>Definition</strong>: Hematology tests focus on the cellular
components of blood.</li>
<li><strong>Common Tests</strong>:
<ul>
<li>RBC (Red Blood Cell Count)</li>
<li>Hemoglobin</li>
<li>Hematocrit</li>
<li>MCV (Mean Corpuscular Volume)</li>
<li>MCH (Mean Corpuscular Hemoglobin)</li>
<li>MCHC (Mean Corpuscular Hemoglobin Concentration)</li>
<li>WBC (White Blood Cell Counts)</li>
<li>Differentiation of white cells (Neutrophils, Lymphocytes, Monocytes,
Eosinophils, Basophils)</li>
</ul></li>
</ul></li>
<li><strong>Blood (or Serum) Chemistry</strong>
<ul>
<li><strong>Definition</strong>: These tests measure the plasma
components of blood, often reflecting the function of various
organs.</li>
<li><strong>Common Tests</strong>:
<ul>
<li>Albumin</li>
<li>LDH (Lactate Dihydrogenase)</li>
<li>Alkaline Phosphatase</li>
<li>Electrolytes (Sodium, Potassium, Chloride, Bicarbonate)</li>
<li>Kidney Function Markers (BUN - Blood Urea Nitrogen, Creatinine)</li>
<li>Liver Enzymes (SGPT/ALT, SGOT/AST, GGT)</li>
<li>Lipid Profile (Cholesterol, Triglycerides)</li>
<li>Others (Phosphorus, Calcium, Total Bilirubin, Total Protein,
Glucose, Uric Acid)</li>
</ul></li>
</ul></li>
<li><strong>Coagulation</strong>
<ul>
<li><strong>Definition</strong>: Coagulation tests assess the blood’s
ability to clot, which is crucial for diagnosing bleeding
disorders.</li>
<li><strong>Common Tests</strong>:
<ul>
<li>Prothrombin Time (PT)</li>
<li>Partial Thromboplastin Time (PTT)</li>
<li>International Normalization Ratio (INR)</li>
</ul></li>
</ul></li>
<li><strong>Urinalysis</strong>
<ul>
<li><strong>Definition</strong>: Tests involving components of urine,
used to detect diseases of the urinary system as well as systemic
conditions.</li>
<li><strong>Common Tests</strong>:
<ul>
<li>Urine pH</li>
<li>Urine Specific Gravity</li>
</ul></li>
</ul></li>
<li><strong>Microbiology</strong>
<ul>
<li><strong>Definition</strong>: These tests identify the presence of
specific bacteria, viruses, and fungi, useful in diagnosing
infections.</li>
<li><strong>Typical Tests</strong>:
<ul>
<li>Cultures from various samples (blood, urine, throat swabs,
etc.)</li>
<li>Sensitivity tests to determine the effectiveness of antibiotics</li>
</ul></li>
</ul></li>
<li><strong>Functional Tests</strong>
<ul>
<li><strong>Definition</strong>: These are grouped analyses of blood
chemistry tests that provide insights into the function of specific
organs or biological systems.</li>
<li><strong>Application</strong>: Commonly used to ensure that a drug is
not adversely affecting a particular organ system.</li>
</ul></li>
</ol>
<table>
<colgroup>
<col width="29%" />
<col width="70%" />
</colgroup>
<thead>
<tr class="header">
<th>System or Organ</th>
<th>Lab Tests</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Liver</strong></td>
<td>ALT, AST, Alkaline Phosphatase, GGT, LDH, Albumin, Bilirubin</td>
</tr>
<tr class="even">
<td><strong>Kidney</strong></td>
<td>BUN, Creatinine</td>
</tr>
<tr class="odd">
<td><strong>Pancreas</strong></td>
<td>Amylase</td>
</tr>
<tr class="even">
<td><strong>Electrolytes</strong></td>
<td>Sodium, Potassium, Chloride</td>
</tr>
<tr class="odd">
<td><strong>Nutritional</strong></td>
<td>Glucose, Fats</td>
</tr>
<tr class="even">
<td><strong>Lipids</strong></td>
<td>Triglycerides, Cholesterol (LDL, HDL)</td>
</tr>
</tbody>
</table>
</div>
<div id="central-labs-vs.-local-labs" class="section level2">
<h2>Central Labs vs. Local Labs</h2>
<p><strong>1. Central Labs</strong> - <strong>Overview</strong>: Central
Labs, like Covance, CCLS, and Quintiles, manage laboratory data for
clinical trials on a larger scale, often globally. -
<strong>Advantages</strong>: - <strong>Standardization</strong>: Tests
are performed using uniform procedures across all samples, enhancing the
comparability of data across different patients and sites. -
<strong>Data Handling</strong>: Results are typically delivered
electronically and include application of normal ranges and unit
standardization as per the trial sponsor’s specifications. -
<strong>Consistency</strong>: Uses a common unit for reporting results,
which can be essential for multi-center international trials. -
<strong>Challenges</strong>: - <strong>Delay in Results</strong>:
Samples must be shipped to the central lab, introducing potential delays
in data availability to investigators.</p>
<p><strong>2. Local Labs</strong> - <strong>Overview</strong>: Local
labs are usually situated within the hospital or medical facility where
the clinical trial is conducted. - <strong>Advantages</strong>: -
<strong>Speed</strong>: Ideal for urgent testing where immediate results
are necessary for patient dosing or trial enrollment decisions. -
<strong>Accessibility</strong>: Convenient for quick data capture
directly into case report forms. - <strong>Challenges</strong>: -
<strong>Lack of Standardization</strong>: Each local lab may use
different units of measurement and have different normal ranges,
complicating data consistency and comparability. - <strong>Data
Integration</strong>: Results from local labs often require additional
efforts to standardize and integrate into the broader trial data
set.</p>
</div>
<div id="units-of-measurements-in-clinical-trials"
class="section level2">
<h2>Units of Measurements in Clinical Trials</h2>
<p><strong>1. Conventional Units</strong> - <strong>Usage</strong>:
Predominantly used in the United States. -
<strong>Characteristics</strong>: These units are familiar to U.S.
healthcare providers and are often derived from historical laboratory
practices.</p>
<p><strong>2. SI Units (Système Internationale)</strong> -
<strong>Usage</strong>: Commonly used in international settings and
preferred for global clinical trials. - <strong>Benefits</strong>:
Facilitates easier comparison and interpretation of clinical trial data
across different countries.</p>
<p><strong>Adaptation for Trials</strong>: - <strong>Single Country
Trials</strong>: It may be simpler to use conventional units if the
trial is confined to the U.S. to align with local clinical practices. -
<strong>International Trials</strong>: SI units are generally preferred
to maintain consistency and ensure clear communication among diverse
international teams.</p>
<p><strong>Dual Reporting</strong>: - In some cases, particularly in
trials spanning multiple countries, results might be reported in both
conventional and SI units to accommodate the preferences and regulatory
requirements of different regions.</p>
</div>
<div id="interpretation-and-use-of-reference-ranges"
class="section level2">
<h2>Interpretation and Use of Reference Ranges</h2>
<p><strong>1. Purpose of Reference Ranges:</strong> - <strong>Diagnostic
Guidance:</strong> Reference ranges help clinicians discern normal from
potentially abnormal results, aiding in diagnosis and treatment
decisions. - <strong>Safety Monitoring:</strong> In clinical trials,
these ranges are used to flag abnormalities and help grade laboratory
toxicities.</p>
<p><strong>2. Challenges with Reference Ranges:</strong> -
<strong>Variability in Establishment:</strong> Labs frequently adopt
reference ranges provided by equipment manufacturers or develop their
own based on internal criteria, which may not be consistent across
different settings. - <strong>Analytical Variability:</strong> Different
labs might optimize assays to varying points within the reference
population range, affecting the sensitivity and specificity of results.
- <strong>Clinical Considerations:</strong> The overlap between disease
and non-disease states in analyte levels can make it challenging to set
definitive range limits without compromising on either sensitivity or
specificity.</p>
<p><strong>3. Determination of Reference Ranges:</strong> -
<strong>Analytical Decisions:</strong> Assay precision must accommodate
the clinical decisions at critical points, which are often at the
extreme ends of the reference range. - <strong>Clinical
Decisions:</strong> Setting the range involves balancing the probability
of correctly identifying an abnormal result (sensitivity) against that
of correctly identifying a normal result (specificity). -
<strong>Mathematical Decisions:</strong> Traditional methods might
include using a small sample of presumed healthy individuals to
establish a 95% reference range. Advanced statistical methods like
bootstrapping or transformations for skewed data are sometimes applied
to refine these ranges.</p>
<p><strong>Implications for Clinical Trials</strong></p>
<p>In the context of clinical trials, especially those involving
multiple laboratories, the use of standard reference ranges can be
problematic: - <strong>Multi-lab Variability:</strong> Different labs
may produce variable results due to differing assay calibrations and
reference standards. - <strong>Normalization Needs:</strong> It has been
suggested that results from different labs should be normalized through
proficiency surveys, where all participating labs analyze a common set
of specimens to ensure compatibility of results. - <strong>Central
Laboratory Use:</strong> Employing a central lab can reduce the need for
adjustments across sites, but does not fully mitigate the issues
associated with reference range construction.</p>
</div>
</div>
<div id="tabulation-summaries-for-laboratory-results"
class="section level1">
<h1>Tabulation Summaries for Laboratory Results</h1>
<p>In clinical trials, lab summaries play a crucial role in interpreting
and communicating the effects of interventions. These summaries are
tailored based on the objectives of the trial and are designed to
provide clear and concise data analysis to support study findings.</p>
<p>Routine analyses of laboratory data include constructing tables that
show the percentage of patients with each specific type of laboratory
abnormality, tables that contain the frequencies of subjects’
experiencing a change from normal to abnormal status or from abnormal to
normal status for each selected body function, tables that contain the
frequencies of subjects’ experiencing a change in their pretreatment
laboratory toxicity grade, and tables that present the summary
statistics concerning the amount of change. Frequently, graphs depict
the amount of change in relation to the pretreatment value, or the
average group change over time. For statistical inference, nonparametric
tests are frequently appropriate even though p-values from the
inferential procedures are typically used for descriptive purpose only.
Recently, some authors have discussed more informative graphic displays.
In addition, multiple small figures that display laboratory data can
also be quite informative.</p>
<div id="typical-summaries" class="section level2">
<h2>Typical Summaries</h2>
<div id="descriptive-statistics-table" class="section level3">
<h3>Descriptive Statistics Table</h3>
<ul>
<li><strong>Purpose</strong>: To provide a statistical summary of
laboratory values at various time points throughout the trial.</li>
<li><strong>Common Statistics</strong>:
<ul>
<li><strong>Mean and Median</strong>: Indicate the central tendency of
the data.</li>
<li><strong>Standard Deviation</strong>: Measures the dispersion or
variability of the lab values from the mean.</li>
<li><strong>Minimum and Maximum</strong>: Show the range of the
data.</li>
</ul></li>
<li><strong>Usage</strong>: This table is often repeated for each lab
test conducted during the trial, offering a snapshot of changes or
percent changes from baseline at predefined visits.</li>
</ul>
</div>
<div id="shift-tables" class="section level3">
<h3>Shift Tables</h3>
<ul>
<li><strong>Purpose</strong>: Used when variations in lab results
complicate direct comparison, often due to the use of local labs.</li>
<li><strong>Content</strong>:
<ul>
<li><strong>Classification</strong>: Lab values are categorized as
“Above Normal Range,” “Within Normal Range,” or “Below Normal
Range.”</li>
<li><strong>Summary</strong>: These categories are analyzed for shifts
from baseline to subsequent time points, often focusing on the last
visit.</li>
</ul></li>
<li><strong>Usage</strong>: Particularly useful in studies with high
variability in data or when comparing results across multiple sites that
might not use standardized measurement units.</li>
</ul>
</div>
<div id="clinically-significant-categories-table"
class="section level3">
<h3>Clinically Significant Categories Table</h3>
<ul>
<li><strong>Purpose</strong>: To categorize lab values into clinically
significant categories based on predefined critical values.</li>
<li><strong>Content</strong>:
<ul>
<li><strong>Categories</strong>: Lab results are segmented into critical
levels, such as “Below a certain threshold” which might indicate a risk
or require intervention.</li>
<li><strong>Patient Count</strong>: Reports the number of patients
falling into each category.</li>
</ul></li>
<li><strong>Usage</strong>: Helps in assessing the clinical relevance of
lab results, particularly in safety analyses.</li>
</ul>
</div>
<div id="standard-ctc-toxicity-grading-table" class="section level3">
<h3>Standard CTC Toxicity Grading Table</h3>
<ul>
<li><strong>Purpose</strong>: To group lab values based on established
toxicity grades, often using Common Terminology Criteria for Adverse
Events (CTC).</li>
<li><strong>Content</strong>:
<ul>
<li><strong>Grading</strong>: Each lab value is assigned a grade (e.g.,
Grade 1, Grade 2) based on severity according to toxicity criteria.</li>
<li><strong>Summary</strong>: Number of patients corresponding to each
toxicity grade at different time points.</li>
</ul></li>
<li><strong>Usage</strong>: Crucial for evaluating drug safety and
managing patient care, particularly in oncology trials where toxicity
monitoring is integral.</li>
</ul>
</div>
</div>
<div id="multivariate-analysis" class="section level2">
<h2>Multivariate Analysis</h2>
<p>The analysis of laboratory data in clinical trials often extends
beyond individual test results to include comprehensive evaluations of
multiple parameters simultaneously. This approach recognizes the
interrelated nature of various biomarkers and their collective impact on
a patient’s health. The multivariate analysis of lab data can enhance
the understanding of a drug’s safety profile and provide a more accurate
representation of clinical outcomes.</p>
<p><strong>1. Preference for Multivariate Analysis</strong></p>
<ul>
<li><p><strong>Comprehensive Safety Profiles:</strong> Clinicians and
researchers increasingly prefer to evaluate a patient’s overall safety
profile using multivariate laboratory data rather than isolating single
parameters. This holistic view helps in making more informed clinical
decisions as it incorporates the complex interactions among various
biomarkers.</p></li>
<li><p><strong>Limitations of Univariate Analysis:</strong> Analyzing
lab results one parameter at a time can lead to a fragmented
understanding of patient health and may overlook the interactions
between different body functions.</p></li>
</ul>
<p><strong>2. Methods and Approaches</strong></p>
<ul>
<li><p><strong>Ranking and Pair Analysis:</strong> Brown et
al. demonstrated a method involving the selection of tolerable limits
for lab results and ranking abnormalities by the frequency of abnormal
values detected. They then analyzed related test results concurrently to
assess the safety of two antibiotics, leveraging the relationship
between tests that assess similar functions.</p></li>
<li><p><strong>Score Construction:</strong> Sogliero-Gilbert et al. and
Gilbert et al. introduced the concept of constructing scores, such as
the Genie score, which aggregates results from multiple related assays
into a single score for each patient. This score can then be used to
compare the effects of different treatments within a clinical trial,
offering a consolidated view of the impact on patient health.</p></li>
<li><p><strong>Incorporating Various Data Types:</strong> Chuang-Stein
et al. suggested a more inclusive approach that combines laboratory
results with other types of safety data, including clinical signs and
symptoms. This method provides a more comprehensive safety profile of
patients by integrating various dimensions of health data.</p></li>
</ul>
<p><strong>3. Benefits of Multivariate Analysis</strong></p>
<ul>
<li><p><strong>Enhanced Data Interpretation:</strong> By aggregating
related lab tests, researchers can achieve a more nuanced understanding
of treatment effects on specific body functions.</p></li>
<li><p><strong>Efficiency in Comparisons:</strong> Collapsing
multivariate data into univariate scores simplifies the statistical
analysis and can lead to more efficient comparisons among different
treatment groups.</p></li>
</ul>
</div>
<div id="regression-to-the-mean" class="section level2">
<h2>Regression to the Mean</h2>
<ul>
<li><p><strong>Eligibility Criteria Impact:</strong> In many clinical
trials, subjects are selected based on specific eligibility criteria,
such as normal ranges for certain laboratory tests like SGOT and SGPT.
Subjects with values too high or too low are typically
excluded.</p></li>
<li><p><strong>Baseline Measurements:</strong> The initial measurement
(screen value) is used as a baseline to compare subsequent laboratory
results. If the initial screening selects subjects based on extreme
values, any natural variation towards the average (mean) can appear as a
change due to the treatment, rather than simple statistical
regression.</p></li>
<li><p><strong>Mean Change Due to Regression:</strong> Chuang-Stein
discussed how the mean change observed in a clinical trial can be
influenced significantly by regression to the mean, especially if the
correlation between the repeated measures is low.</p></li>
<li><p><strong>Impact of Exclusion Criteria:</strong> The stricter the
exclusion criteria (e.g., only allowing subjects with values within a
narrow range), the more pronounced the regression effect can be. This
can erroneously suggest that treatment has affected parameters like SGOT
and SGPT when, in fact, it has not.</p></li>
</ul>
<p><em>Source: Chuang-Stein C. The regression fallacy. Drug Info J
1993;27:1213–1220.</em></p>
<p><strong>Adjustment Procedures</strong></p>
<ul>
<li><strong>Proposed Adjustments:</strong> Chuang-Stein proposed
specific adjustments to account for the regression effect, aiming to
provide a more accurate assessment of how treatments impact laboratory
parameters.</li>
<li><strong>Selection of Baseline Values:</strong> Another approach to
mitigate this effect is the selection of baseline values. Using values
from a pretreatment period closer to the start of dosing rather than
initial screening values can reduce the impact of regression to the
mean.</li>
<li><strong>Controlled Study Settings:</strong> In controlled trials
where subjects are randomized into treatment groups, regression to the
mean is less likely to skew comparisons among groups if the
randomization effectively balances baseline characteristics across these
groups.</li>
<li><strong>Use of Multiple Baseline Measures:</strong> Comparing
changes from a baseline established by multiple pre-treatment measures
can also help mitigate this effect.</li>
</ul>
</div>
<div id="mixture-response-distributions" class="section level2">
<h2>Mixture Response Distributions</h2>
<p>In clinical trials, the response of patients to a treatment is not
always uniform, leading to variations in how different subjects react.
This variation can often be described using mixture distributions, which
provide a statistical framework for modeling the differential response
to treatment across a population.</p>
<ul>
<li><strong>Basic Idea</strong>: The response distribution for a
laboratory parameter in a treatment group might not be homogenous but
could represent a mixture of different distributions. For instance, part
of the treatment group might follow the same distribution as the control
group, while another part might show a significant shift in the response
due to the treatment.</li>
<li><strong>Realistic Modeling of Patient Responses</strong>: The
mixture model approach acknowledges that some patients might not exhibit
any treatment effects (hence the control-like distribution), while
others might experience significant changes in lab parameters due to the
treatment. This dual response can be crucial for understanding the full
impact of a treatment, especially when considering side effects or
therapeutic effectiveness.</li>
<li><strong>Formulation</strong>: Assume <code>G(x)</code> as the
response distribution for the treatment group and <code>F(x)</code> for
the control. <code>G(x)</code> can be modeled as a mixture of
<code>F(x)</code> and a transformed version of <code>F(x)</code> that
includes a location shift <code>D</code> and a scale change
<code>l</code>, formulated as: <span class="math display">\[
G(x) = pF(x) + (1-p)F\left(\frac{x-D}{l}\right)
\]</span> Here, <code>p</code> represents the proportion of the
treatment group that responds similarly to the control group.</li>
</ul>
<p><strong>Statistical Challenges and Solutions</strong></p>
<ul>
<li><strong>Estimation and Hypothesis Testing</strong>: The primary
statistical task is to estimate the mixture proportion <code>p</code>
and test the null hypothesis <span class="math inline">\(H_0: p =
1\)</span> against the alternative <span class="math inline">\(H_1: p
\neq 1\)</span>. This tests whether the treatment has a different effect
compared to the control.</li>
<li><strong>Methodologies Applied</strong>:
<ul>
<li><strong>Cherng et al. [16]</strong> discussed testing procedures
specifically designed for this scenario, applying methods proposed by
<strong>Conover and Salsburg</strong> and <strong>O’Brien</strong>.
These methods help in identifying whether a significant portion of the
treatment group exhibits a response different from the control
group.</li>
</ul></li>
</ul>
</div>
<div id="correlating-lb-data-with-pharmacokinetic-parameters"
class="section level2">
<h2>Correlating LB Data with Pharmacokinetic Parameters</h2>
<p>Pharmacokinetic parameters describe how a drug is absorbed,
distributed, metabolized, and excreted in the body. Laboratory data, on
the other hand, can indicate how these processes affect the body’s
normal functions, revealing potential toxicities or adverse effects.</p>
<p>In the context of drug development and clinical trials, the
correlation between pharmacokinetic (PK) parameters and laboratory data
is crucial for understanding how a drug behaves in the body and its
potential toxic effects. This correlation helps in optimizing drug
dosing, monitoring therapeutic levels, and enhancing overall treatment
safety and efficacy.</p>
<p><strong>Methodological Approaches</strong></p>
<ul>
<li><strong>Toxicity and Drug Concentrations</strong>: Observing severe
toxicities at high plasma drug concentrations provides a direct
rationale for therapeutic drug monitoring. This approach ensures that
drug levels remain within a therapeutic range that maximizes efficacy
while minimizing harm.</li>
<li><strong>Complexity of Analyses</strong>: The relationships between
PK parameters and laboratory data are often complex and require
sophisticated statistical tools to decipher.</li>
<li><strong>Variability</strong>: High inter-individual variability in
how patients process drugs can complicate these analyses, making
universal conclusions difficult.</li>
<li><strong>Statistical Modeling</strong>: Techniques such as regression
analysis, mixed-effects models, and machine learning algorithms can be
used to identify and quantify relationships between PK parameters and
lab data.</li>
<li><strong>Biomarker Development</strong>: Identifying biomarkers that
predict drug response or toxicity can significantly enhance the utility
of PK data, guiding drug dosing and monitoring strategies.</li>
</ul>
<p><strong>Applications of Correlating PK Parameters with Lab
Data</strong></p>
<ol style="list-style-type: decimal">
<li><strong>Therapeutic Drug Monitoring (TDM)</strong>:
<ul>
<li><strong>Purpose</strong>: To adjust drug dosages based on individual
pharmacokinetic profiles and laboratory markers of toxicity or
efficacy.</li>
<li><strong>Example</strong>: If high drug plasma levels are correlated
with laboratory signs of liver toxicity (e.g., elevated liver enzymes),
dosing adjustments might be necessary.</li>
</ul></li>
<li><strong>Effect of Baseline Conditions</strong>:
<ul>
<li><strong>Impact on Drug Absorption and Effectiveness</strong>:
Pre-existing conditions, such as hepatitis B, can influence how a drug
is metabolized and absorbed. Understanding these effects through PK and
laboratory data correlation can guide dosage adjustments and treatment
planning.</li>
<li><strong>Clinical Decision Making</strong>: Analyzing how baseline
health conditions affect drug kinetics can help in predicting treatment
outcomes and personalizing therapies.</li>
</ul></li>
<li><strong>Pharmacodynamic Insights</strong>:
<ul>
<li><strong>Mechanism of Action</strong>: Correlating lab data with PK
parameters can elucidate the pharmacodynamic properties of a drug,
revealing how it exerts its effects at the cellular or systemic
level.</li>
<li><strong>Safety and Efficacy</strong>: This correlation aids in
identifying which pharmacokinetic profiles correspond to optimal
therapeutic outcomes and acceptable safety profiles.</li>
</ul></li>
</ol>
</div>
<div id="patients-at-risk-for-laboratory-toxicity"
class="section level2">
<h2>Patients at Risk for Laboratory Toxicity</h2>
<p>Understanding and predicting laboratory toxicities in various patient
subgroups is crucial for developing safer and more effective treatment
regimens. Traditional clinical trials often exclude patients with major
organ impairments, which limits the understanding of how these
populations might respond to new treatments. However, regulatory bodies
are increasingly requiring the inclusion of diverse patient subgroups to
ensure a comprehensive safety profile.</p>
<p><strong>Challenges in Current Clinical Trials</strong></p>
<ul>
<li><strong>Exclusion of Vulnerable Populations</strong>: Initial phases
of clinical trials commonly exclude patients with significant organ
impairments (like hepatic or renal dysfunctions), which can lead to a
lack of data about how these populations react to the treatments.</li>
<li><strong>Post-Approval Risks</strong>: Once a treatment is approved
and enters the market, it becomes accessible to a broader population,
including those previously excluded from trials, potentially leading to
unforeseen adverse reactions.</li>
</ul>
<p><strong>Regulatory Requirements</strong></p>
<ul>
<li><strong>Inclusive Study Designs</strong>: Regulators are mandating
the inclusion of specific subgroups—such as pediatric, geriatric, and
patients with existing organ dysfunctions—in clinical trials to evaluate
the safety profiles more comprehensively.</li>
<li><strong>Exploratory Analyses</strong>: These are conducted to
identify risk factors associated with the onset, presence, or severity
of laboratory toxicities.</li>
</ul>
<p><strong>Statistical Methods for Safety Analysis</strong></p>
<ul>
<li><strong>Logistic Regression</strong>: Useful for identifying
predictors of binary outcomes, such as the occurrence of a specific
toxicity. It helps in understanding which factors (e.g., age, baseline
organ function) increase the likelihood of adverse reactions.</li>
<li><strong>Survival Analysis</strong>: Applied to examine the time to
onset of adverse reactions. This method can handle censored data (where
patients drop out or the study ends before an event occurs) and can
provide insights into the timing of toxicities.</li>
</ul>
</div>
</div>
<div id="graphical-summaries-for-laboratory-results"
class="section level1">
<h1>Graphical Summaries for Laboratory Results</h1>
<p>Graphical summaries are invaluable in clinical trials for visually
representing laboratory data over time, comparing treatment groups, and
identifying outliers that may require further investigation.</p>
<div id="typical-summaries-1" class="section level2">
<h2>Typical Summaries</h2>
<div id="box-and-whisker-plot" class="section level3">
<h3>Box and Whisker Plot</h3>
<ul>
<li><strong>Description</strong>: This plot is highly effective for
depicting the distribution of lab data across different visits within a
treatment group.</li>
<li><strong>Components</strong>:
<ul>
<li><strong>Median</strong>: The line in the middle of the box indicates
the median value of the dataset.</li>
<li><strong>Interquartile Range (IQR)</strong>: The box represents the
25th to 75th percentile.</li>
<li><strong>Whiskers</strong>: Extend from the box to 1.5 times the IQR,
indicating the range of most data points.</li>
<li><strong>Outliers</strong>: Data points that fall outside the
whiskers are plotted individually, often marked with a specific
symbol.</li>
</ul></li>
<li><strong>Usage</strong>: Ideal for showing the central tendency
(median) and variability (IQR) of data over time, and for spotting
outliers at each visit.</li>
</ul>
<p><strong>SAS Implementation</strong></p>
<pre class="sas"><code>axis1 label=(angle=90 &#39;Parameter Name&#39;) &amp;order;
axis2 label=(&#39;WEEK OF STUDY&#39;) offset=(0.5 in);
symbol1 interpol=boxt value=x;
proc gplot data=plotds;
plot &amp;var*visn / noframe vaxis=axis1 haxis=axis2;</code></pre>
</div>
<div id="mean-and-standard-deviation-plot" class="section level3">
<h3>Mean and Standard Deviation Plot</h3>
<ul>
<li><strong>Description</strong>: This type of plot compares the mean
lab values across treatment groups over time, incorporating error bars
to represent one standard deviation above and below the mean.</li>
<li><strong>Steps</strong>:
<ul>
<li><strong>Data Preparation</strong>: Calculate the mean and standard
deviation for each treatment group at each visit.</li>
<li><strong>Plotting</strong>: Display mean values connected by lines,
with error bars showing the range of one standard deviation.</li>
</ul></li>
<li><strong>Usage</strong>: Useful for directly comparing the mean
responses of treatment groups over time and visualizing the data
spread.</li>
</ul>
<p><strong>SAS Implementation</strong></p>
<pre class="sas"><code>proc univariate data=deff_n noprint;
by parm trtname visit;
var lbstresn;
output out=deff_v n=n1 mean=mean1 std=sd1;
data deff_v; set deff_v; by parm trtname visit;
val=mean1; output;
val=mean1+sd1; output;
val=mean1-sd1; output;

symbol1 l=1 value=diamond width=3 interpol=hiloj line=1;
symbol2 l=1 value=square width=3 interpol=hiloj line=5;
legend1 across=1 cborder=black label=none position=(top inside center) across=2 value=(&quot;TRTA(1-4 MG QID)&quot; &quot;&amp;ztrtb&amp;ztrtbb&quot;);
proc gplot data=ps nocache;
plot val*window=trtname / vaxis=axis1 haxis=axis2 legend=legend1;</code></pre>
</div>
</div>
<div id="edish" class="section level2">
<h2>eDISH</h2>
</div>
</div>
<div id="presentation-and-handling-of-clinical-laboratory-data"
class="section level1">
<h1>Presentation and Handling of Clinical Laboratory Data</h1>
<p>The following figure is provided as example to display the mean
changes in laboratory values over time and is presented in clinically
relevant groupings based on the template.</p>
<p><img src="./02_Plots/LB_Mean" /></p>
<p><em>Jagadish K., <a
href="https://www.linkedin.com/posts/jagadishkatam_r-rstudio-datascience-activity-7132144850254123008-yylO/?utm_source=share&amp;utm_medium=member_desktop"
class="uri">https://www.linkedin.com/posts/jagadishkatam_r-rstudio-datascience-activity-7132144850254123008-yylO/?utm_source=share&amp;utm_medium=member_desktop</a></em></p>
<pre><code>labs &lt;- function(data, params, val){
  # Filter data based on parameters and visit
  adlbcx &lt;- data[data$PARAMCD == params &amp; data$AVISIT != &#39;&#39;, ]

  # Summarize data to calculate mean, sd, se, CI lower and upper bounds
  adlbc1 &lt;- adlbcx %&gt;%
    group_by(TRTA, AVISIT) %&gt;%
    summarise(
      mean = mean(val, na.rm = TRUE),
      sd = sd(val, na.rm = TRUE),
      n = n(),
      se = sd / sqrt(n),
      CI_lower = mean - 1.96 * se,
      CI_upper = mean + 1.96 * se,
      .groups = &#39;drop&#39;
    )

  # Prepare for joining by renaming and transforming
  adlbcn &lt;- adlbcx %&gt;%
    rename_all(tolower) %&gt;%
    group_by(trta, trtan, avisit, avisitn) %&gt;%
    summarise(n = n(), .groups = &#39;drop&#39;) %&gt;%
    left_join(adlbc1, by = c(&quot;trta&quot;, &quot;trtan&quot;, &quot;avisit&quot;, &quot;avisitn&quot;)) %&gt;%
    mutate(across(contains(&quot;.&quot;), ~round(.x, digits = 1)))

  return(adlbcn)
}

# Generate a plot using ggplot2
g1 &lt;- ggplot(data = adlbcn, aes(x = reorder(avisit, avisitn), y = mean, group = trta)) +
  geom_point(aes(color = trta), size = 1.5, position = position_dodge(width = 0.7)) +
  geom_line(aes(color = trta, linetype = trta), position = position_dodge(width = 0.7)) +
  geom_errorbar(aes(ymin = CI_lower, ymax = CI_upper, color = trta), position = position_dodge(width = 0.7)) +
  theme_classic() +
  theme(legend.position = &quot;bottom&quot;) +
  scale_linetype(guide = FALSE) +
  guides(color = guide_legend(title = &quot;Treatment&quot;)) +
  labs(x = &quot;Visit&quot;, y = &quot;Mean Change from Baseline (95% CI)&quot;) +
  geom_hline(yintercept = 0, linetype = &#39;dashed&#39;)

# Plot number of patients
t2 &lt;- ggplot(data = adlbcn, aes(x = reorder(avisit, avisitn), y = trta, label = as.character(n))) +
  geom_text(aes(color = &#39;white&#39;), vjust = -0.5, hjust = 0.5) +
  ggtitle(&quot;Number of Patients&quot;) +
  theme_bw() +
  theme(
    axis.line = element_blank(),
    panel.grid = element_blank(),
    axis.ticks = element_blank(),
    axis.title = element_blank(),
    axis.text.x = element_text(color = &quot;white&quot;),
    plot.title = element_text(size = 11, hjust = 0)
  )

# Combine plots
library(patchwork)
combined_plot &lt;- g1 + t2 + plot_layout(ncol = 1, nrow = 2, heights = c(2, 1))</code></pre>
</div>
<div id="reference" class="section level1">
<h1>Reference</h1>
<div id="general" class="section level2">
<h2>General</h2>
<ul>
<li>Christy Chuang-Stein; PhD (1998). Laboratory Data in Clinical
Trials: A Statistician’s Perspective. , 19(2), 167–177. <a
href="doi:10.1016/s0197-2456(97)00123-2"
class="uri">doi:10.1016/s0197-2456(97)00123-2</a></li>
<li>Carlson, Randall K. “Approaches For Using SAS for Conversion of
Pharmaceutical Safety Laboratory Values to Standard Units”, 19th Annual
Conference Proceedings of the Northeast SAS® Users Group, September
2006</li>
<li>Carlson, R. K., &amp; Freimark, N. (n.d.). Presentation and Handling
of Clinical Laboratory Data: From Test Tube to Table. Wilmington, DE
&amp; Lakewood, NJ: Omnicare Clinical Research, Inc. <a
href="https://www.lexjansen.com/nesug/nesug07/np/np02.pdf"
class="uri">https://www.lexjansen.com/nesug/nesug07/np/np02.pdf</a></li>
</ul>
</div>
<div id="multivariate-analysis-1" class="section level2">
<h2>Multivariate Analysis</h2>
<ul>
<li>Brown KR, Getson AJ, Gould AL, et al. Safety of cefoxitin: an
approach to the analysis of laboratory data. Rev Infectious Dis
1979;1:228–231.</li>
<li>Sogliero-Gilbert G, Mosher K, Zubkoff L. A procedure for the
simplification and assessment of lab parameters in clinical trials. Drug
Info J 1986;20:279–296.</li>
<li>Gilbert GS, Ting N, Zubkoff L. A statistical comparison of drug
safety in controlled clinical trials: the Genie score as an objective
measure of lab abnormalities. Drug Info J 1991;25:81–96.</li>
<li>Chuang-Stein C, Mohberg NR, Musselman DM. The organization and
analysis of safety data using a multivariate approach. Stat Med
1992;11:1075–1089.</li>
</ul>
</div>
<div id="mixture-response-distributions-1" class="section level2">
<h2>Mixture Response Distributions</h2>
<ul>
<li>Conover WJ, Salsburg DS. Locally most powerful tests for detecting
treatment effects when only a subset of patients can be expected to
“respond” to treatment. Biometrics 1988;44:189–196.</li>
<li>O’Brien PC. Comparing two samples: Extensions of the t, rank-sum,
and log-rank tests. JASA 1988;83:52–61.</li>
</ul>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
